|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017337,
umls-concept:C0021745,
umls-concept:C0086418,
umls-concept:C0443199,
umls-concept:C0871261,
umls-concept:C1312248,
umls-concept:C1334078,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1825561,
umls-concept:C2003941,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1991-5-9
|
|
pubmed:abstractText |
9-27 mRNA is expressed to a high level in response to both alpha and gamma interferons. In contrast, 6-16 mRNA is expressed well in response to alpha but very poorly in response to gamma interferon in human cells. The factors governing these different levels of expression were investigated. For both genes the major effect of both interferons is on transcription. A transcriptional bias in the 6-16 promoter/enhancer accounts in large part for the differential response of 6-16 to the two interferons. No single DNA element appears responsible; the smaller the 5' region analysed the lower the absolute activity and the smaller the differential response to alpha and gamma interferons observed. Both the 6-16 and 9-27 mRNAs are very stable and no effect of the interferons on stability was detected. Nor was any direct evidence obtained for preferential processing of the 9-27 mRNA. Nevertheless, differentials between the transcription and accumulation of mature mRNAs, particularly for 6-16 mRNA in response to gamma interferon, suggest that post-transcriptional control(s) must additionally operate. The 9-27 5' promoter/enhancer is much less active than that from 6-16 when placed 5' of a marker gene, despite the similar response of the two genes to alpha interferon.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2141169,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2456211,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2457496,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2467742,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2492664,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2498080,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2507314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2721502,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2824996,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2860635,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2919169,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-2974922,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-3017706,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-3037497,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-3095442,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-3097644,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-3106967,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-3359997,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-3371658,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-3476954,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-3935435,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-6292901,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-6312838,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-6548414,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-6960240,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1901407-7175502
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0305-1048
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
11
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
591-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:1901407-Blotting, Northern,
pubmed-meshheading:1901407-Cells, Cultured,
pubmed-meshheading:1901407-DNA Mutational Analysis,
pubmed-meshheading:1901407-Enhancer Elements, Genetic,
pubmed-meshheading:1901407-Gene Expression Regulation,
pubmed-meshheading:1901407-Genes,
pubmed-meshheading:1901407-Humans,
pubmed-meshheading:1901407-Interferon Type I,
pubmed-meshheading:1901407-Interferon-gamma,
pubmed-meshheading:1901407-Metabolic Clearance Rate,
pubmed-meshheading:1901407-Multigene Family,
pubmed-meshheading:1901407-Promoter Regions, Genetic,
pubmed-meshheading:1901407-RNA, Messenger,
pubmed-meshheading:1901407-RNA Processing, Post-Transcriptional,
pubmed-meshheading:1901407-Recombinant Proteins,
pubmed-meshheading:1901407-Transcription, Genetic
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
Differential response of the human 6-16 and 9-27 genes to alpha and gamma interferons.
|
|
pubmed:affiliation |
Imperial Cancer Research Fund, London, UK.
|
|
pubmed:publicationType |
Journal Article
|
